furosemide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   79 Trials   79 Trials   6783 News 


«12...6667686970717273747576...8687»
  • ||||||||||  Doburan (dobutamine) / VHB Life Sciences, furosemide / Generic mfg., Cardilor (amiodarone) / Generic mfg.
    [VIRTUAL] THE DISTANCE A HEART CAN TRAVEL: THE BENEFITS OF A NEW HEART DONOR ALLOCATION SYSTEM (eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_4604;    
    She was started on dobutamine and furosemide drip...She developed recurrent SVT and was started on an amiodarone drip, but developed severe hypotension and required vasopressor support... Our patient received a heart transplant within 3 days of being listed as status 1 due to the new geographical range in organ donation and change in policies.
  • ||||||||||  furosemide / Generic mfg.
    [VIRTUAL] TWISTS AND TURNS: AN UNUSUAL INTRA-ABDOMINAL CAUSE OF HEART FAILURE (eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_4603;    
    Increased intra-abdominal pressures from a sigmoid volvulus can cause an increase in preload leading to clinical symptoms of heart failure. Abdominal processes should be considered as causes of recurrent heart failure exacerbations, and may need surgical interventions to facilitate long lasting symptomatic relief.
  • ||||||||||  enalapril / Generic mfg., Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Clinical, Journal:  Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. (Pubmed Central) -  Dec 20, 2019   
    Almost half of the patients reached the maximal dose, with a tolerability profile in line with the original study. Treatment with sacubitril/valsartan was associated with more loop diuretic dose reductions and fewer dose increases compared with enalapril, suggesting that treatment with sacubitril/valsartan may reduce the requirement for loop diuretics relative to enalapril in patients with heart failure with reduced ejection fraction.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Clinical, Journal:  Primary aldosteronism in Klinefelter's syndrome: two cases. (Pubmed Central) -  Dec 17, 2019   
    Expression of luteinizing hormone receptor has been reported in aldosterone-producing adenoma. Serum luteinizing hormone, which is increased in patients with Klinefelter's syndrome, might contribute to the development of primary aldosteronism.
  • ||||||||||  furosemide / generics
    Clinical, Journal:  Acute Kidney Injury After Pediatric Liver Transplantation. (Pubmed Central) -  Dec 6, 2019   
    We evaluated that hypoalbuminemia, high requirement for RBC and 20% human albumin transfusions, high serum sodium, high furosemide use, and high flow of ascites are risk factors for AKI and high BUN levels can be predictive for AKI in pediatric LT patients. The effect of AKI on outcome variables were prolonged mechanical ventilation and hospital LOS.
  • ||||||||||  Simdax (levosimendan IV) / AbbVie
    Retrospective data, Review, Journal:  Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis. (Pubmed Central) -  Nov 28, 2019   
    In the present meta-analysis, levosimendan infusion in patients with ADHF appeared to reduce BNP regardless of the comparator (except for dopamine), and also improve LVEF and increase HR in after vs. before use comparisons but not compared to controls. Future larger studies on the benefit of levosimendan in ADHF patients are warranted.
  • ||||||||||  furosemide / generics
    Preclinical, Journal:  Characterization of renal NaCl and oxalate transport in Slc26a6-/- mice. (Pubmed Central) -  Nov 28, 2019   
    Moreover, the increments in urine flow rate and sodium excretion following thiazide and furosemide infusion were identical in wild-type and Slc26a6 mice, indicating no difference in NaCl delivery out of the proximal tubule...In contrast to the lack of effect of SLC26A6 deletion on NaCl homeostasis, fractional excretion of oxalate was reduced from 1.6 in wild-type mice to 0.7 in Slc26a6-/- mice. We conclude that although SLC26A6 is dispensable for renal NaCl homeostasis, it is required for net renal secretion of oxalate.
  • ||||||||||  furosemide / generics
    Preclinical, Journal:  Furosemide Reduces BK-αβ4-mediated K+ Secretion in Mice on an Alkaline High K+ Diet. (Pubmed Central) -  Nov 28, 2019   
    Acetazolamide plus furosemide also restored the cortical expression of BK-β4 and BK-α in connecting tubules (CNT). These results indicate that in mice adapted to HK, furosemide reduces BK-αβ4-mediated K secretion by acidifying the urine.
  • ||||||||||  Doburan (dobutamine) / VHB Life Sciences, Kineret (anakinra) / SOBI, Affibody
    Clinical, Journal:  Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. (Pubmed Central) -  Nov 27, 2019   
    However, in view of the two different and simultaneous evolutions, the girl showed Kawasaki disease with late coronary artery lesions and aneurysms, whereas the brother showed Kawasaki shock syndrome with myocardial dysfunction. We stress the effectiveness of anakinra in non-responder Kawasaki disease and the efficacy on coronary aneurysms.
  • ||||||||||  Clinical, Journal:  Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia. (Pubmed Central) -  Nov 27, 2019   
    New York Heart Association (NYHA) class III (Adjusted odds ratio (AOR):0.12, 95% confidence interval (CI):0.02-0.98), valvular heart disease (AOR: 0.27, 95% CI: 0.13-0.56), hypertension (AOR: 5.82, 95% CI: 2.16-15.71), and diabetes mellitus (AOR: 3.84, 95% CI: 1.07-13.86) were significantly associated with the use of ACEIs, whereas age ≥65 (AOR: 2.61, 95%CI: 1.20-5.64), previous hospitalization for heart failure (AOR: 2.08, 95%CI: 1.11-3.92), diuretic use (AOR: 5.60, 95%CI: 2.75-11.40), and dose of furosemide >40mg (AOR: 9.80, 95%CI: 3.00-31.98) were predictors of suboptimal dosing of ACEIs...Valvular heart disease and NYHA class III were negatively associated with the use of ACEIs while previous hospitalization for heart failure, old age, diuretic use, and diuretic dose were predictors of suboptimal dosing of ACEIs. Therefore, more effort needs to be done to minimize the potentially modifiable risk factors of suboptimal use of ACEIs therapy in heart failure patients.
  • ||||||||||  furosemide / generics
    Preclinical, Journal:  Developing a predictive in vitro dissolution model based on gastrointestinal fluid characterisation in rats. (Pubmed Central) -  Nov 27, 2019   
    Based on these observations, biorelevant media were developed to simulate fluids in the stomach and the proximal part of the small intestine in fasted rats. The media were implemented in a two-step in vitro dissolution model, which was found to better predict the in vivo performance of furosemide, when compared to previously published in vitro and in vivo data.